GRACEcast

By Howard (Jack) West, MD

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Edu... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.

GRACEcast episodes:

June 11, 2014 What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?
Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.
...more
4min
June 09, 2014 How Do We Make EGFR Inhibitors Work Better for Patients
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
...more
4min
June 04, 2014 TH 302: New Drug May Make Tumors Less Resistant to Treatment
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
...more
2min
June 01, 2014 Should We Do Broad Sequencing of All Lung Tumors?
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.
...more
4min
May 29, 2014 How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
...more
5min
May 27, 2014 Why Are Non-Mutated EGFR Genes Called "Wild Type?"
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.
...more
2min
May 25, 2014 Teaching the Immune System to Attack Lung Cancer Tumors
Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.
...more
7min
May 22, 2014 Advice for Lung Cancer Patients: Know Thy Cancer
What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they have and which, if any, mutations their lung tumors may have. He explains why in this video.
...more
2min
May 21, 2014 Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?
If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.
...more
2min
May 19, 2014 Treating EGFR Patients After Tarceva Stops Working
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.
...more
3min

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.